Tenaya Therapeutics Presents Promising Data for TN-301 in Phase 1 Clinical Trial at HFSA Annual Scientific Meeting

Tenaya Therapeutics, a clinical-stage biotechnology company focused on developing potentially curative therapies for heart disease, has unveiled new data for its investigational drug TN-301 at the 2023 Heart Failure Society of America (HFSA) Annual Scientific Meeting. TN-301 is a highly selective small molecule inhibitor of histone deacetylase 6 (HDAC6) being developed for the treatment of heart failure with preserved ejection fraction (HFpEF).

The Phase 1 clinical trial of TN-301 demonstrated promising results, showing safety, tolerability, and target engagement in healthy participants. The trial also indicated the potential for once-daily dosing, with dose-proportional pharmacokinetics. These findings support the continued development of TN-301 as a potential treatment option for HFpEF, a form of heart failure with limited treatment options and low survival rates.

Furthermore, Tenaya researchers conducted preclinical studies to explore the combination of their HDAC6 inhibitor, TYA-018, with empagliflozin, an approved sodium-glucose cotransporter-2 (SGLT2) inhibitor for HFpEF. The study demonstrated additive benefits in cardiac structural and functional measures, highlighting the differentiated mechanism of action of the combination therapy.

HFpEF is characterized by a stiffening of the heart muscle, leading to impaired relaxation during normal heart rhythm. It accounts for approximately 50 percent of all heart failures, yet there are few proven treatment options available. TN-301, with its multi-modal mechanism of action, has shown promise in preclinical studies by reversing signs and symptoms of HFpEF, improving cardiac function, glucose tolerance, and reducing inflammation and fibrosis.

Tenaya Therapeutics is committed to discovering, developing, and delivering potentially curative therapies for heart disease. In addition to TN-301, the company has other candidates in its pipeline, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).

With these encouraging results, Tenaya Therapeutics is poised to make a significant impact in the field of heart disease treatment. Continued development of TN-301 and other innovative therapies may offer hope to the many HFpEF patients who are currently underserved by existing treatment options.

For more information about Tenaya Therapeutics and its pipeline, visit www.tenayatherapeutics.com.